Oppenheimer initiates Guardian Pharmacy stock with Outperform rating

Investing.com - Oppenheimer initiated coverage on Guardian Pharmacy Services Inc. (NYSE:GRDN) with an Outperform rating and a $30.00 price target on Friday. The company, currently valued at $1.5 billion, has generated revenue of $1.3 billion in the last twelve months, according to InvestingPro data.

The research firm cited Guardian Pharmacy’s position as a leading pharmacy services company that provides technology-enabled services to long-term care facility residents, with a focus on assisted living facilities.

Guardian currently operates 52 pharmacies serving approximately 195,000 residents across roughly 7,400 long-term care facilities, according to Oppenheimer’s research note.

Oppenheimer’s favorable outlook is based on several factors, including the fragmented market opportunity with potential for consolidation, growing demand for services, stable margin profile, and Guardian’s consistent track record.

While the firm acknowledged that upcoming reimbursement changes related to maximum fair price add some uncertainty, it believes the impact will be manageable and that these concerns are already reflected in Guardian’s stock price.

In other recent news, Guardian Pharmacy Services reported a 15% increase in revenue for the second quarter of 2025, reaching $344.3 million. The company’s earnings per share (EPS) were $0.23, which met analysts’ expectations. Truist Securities raised its price target for Guardian Pharmacy Services to $30, up from $28, while maintaining a Buy rating. Truist cited the company’s strong market positioning and robust demand in its core business as reasons for the increased target. The firm also noted Guardian’s significant market share across many of its pharmacy locations. These developments reflect Guardian’s continued growth and stability in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.